ArticleMedicine2025
Research on the potential mechanisms of propofol in treating depression after brain injury based on network pharmacology.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe precise mechanisms by which propofol exerts neuroprotective and antidepressant effects have not been fully elucidated. This study aimed to clarify how propofol alleviates depression following brain injury using a network pharmacology approach.
methodsBy implementing strategies rooted in network pharmacology, we predicted shared target genes of propofol relevant to the treatment of traumatic brain injury, ischemic brain injury, and depression. We analyzed interactions and pathway enrichment through protein-protein interaction networks, along with Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. Potential protein targets were subjected to molecular docking with propofol using AutoDock Vina software.
resultsAfter screening, we identified 22 intersection targets corresponding to 88 Gene Ontology entries and 20 Kyoto Encyclopedia of Genes and Genomes signaling pathways. The key targets primarily include core proteins such as gamma-aminobutyric acid receptors, glutamate receptors, dopamine receptors, and cation channels. Molecular docking simulations confirmed the stable binding of propofol to the 10 key targets.
conclusionThis study sheds light on the possible mechanisms by which propofol affects depression in the aftermath of brain injury. Future studies should utilize a network pharmacology framework to explore further the corresponding targets and pathways implicated in the therapeutic effect of propofol on depression after brain injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.